Download this Paper Open PDF in Browser

Of Evergreening and Efficacy: The Glivec Patent Case

GESPAM, 2011

7 Pages Posted: 2 May 2013  

Ryan Abbott

University of Surrey School of Law; University of California, Los Angeles - David Geffen School of Medicine

Date Written: April 29, 2013

Abstract

An important case was decided this month that may have a significant impact on access to medicines for patients in developing countries. India’s high court rejected an appeal by the pharmaceutical company Novartis to grant a patent for its anti-cancer drug Glivec. In the aftermath of this case, it is more likely other countries will follow India's lead.

Keywords: Patents, Access to Medicines, Novelty, Glivec, India

Suggested Citation

Abbott, Ryan, Of Evergreening and Efficacy: The Glivec Patent Case (April 29, 2013). GESPAM, 2011. Available at SSRN: https://ssrn.com/abstract=2258904

Ryan Benjamin Abbott (Contact Author)

University of Surrey School of Law ( email )

Guildford
Guildford, Surrey GU2 5XH
United Kingdom

University of California, Los Angeles - David Geffen School of Medicine ( email )

1000 Veteran Avenue, Box 956939
Los Angeles, CA 90095-6939
United States

Paper statistics

Downloads
177
Rank
142,664
Abstract Views
632